Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5475 metabolism and excretion study in healthy volunteers
NCT06777602Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of frespaciguat, sponsored by Merck & Co. Primary endpoints: Amount Excreted in Urine up to 23 days, Cumulative Amount Excreted in Urine up to 23 days and 13 more. Started Aug 2022; status: completed.
02
Drugs
frespaciguat
Beyond the preview
Go deeper on NCT06777602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06777602.